Study in Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics Between Early- and Late-Onset Pancreatic Neuroendocrine Tumors: A Multicenter Retrospective Study
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Enrollment
- 600
- Locations
- 2
- Primary Endpoint
- Overall Survival
Study Overview
Brief Summary
The aim of this observational multicenter retrospective cohort study is to evaluate the differences in risk factors, prognosis, clinicopathological and metabolic characteristics between early-onset pancreatic neuroendocrine tumors (EO-PanNETs) and late-onset pancreatic neuroendocrine tumors (LO-PanNETs).
The main questions it aims to answer are:
Are there distinct clinical, pathological, and metabolic profiles in EO-PanNETs compared with LO-PanNETs? Do EO-PanNETs have different prognostic outcomes compared with LO-PanNETs? Researchers will compare EO-PanNET patients with LO-PanNET patients and with matched nonmalignant controls to assess differences in tumor characteristics and associated metabolic conditions.
Participants will:
Provide retrospective clinical, pathological, and metabolic data from hospital records.
Have survival and recurrence outcomes assessed through follow-up data review.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to 85 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •18 years or older; histopathologically confirmed pancreatic neuroendocrine tumor by surgical resection or biopsy.
Exclusion Criteria
- •Pancreatic neuroendocrine carcinoma; incomplete pathological data; received antitumor treatment prior to presentation; with other malignanies or malignant history.
Arms & Interventions
Early-onset pancreatic neuroendocrine tumors group
This group comprises patients diagnosed with pancreatic neuroendocrine tumors before the age of 50 years. All cases were histopathologically confirmed and treated at one of the participating centers.
Late-onset pancreatic neuroendocrine tumors group
This group comprises patients diagnosed with pancreatic neuroendocrine tumors at or after the age of 50 years. All cases were histopathologically confirmed and treated at one of the participating centers.
Outcomes
Primary Outcomes
Overall Survival
Time Frame: From date of randomization until the date of death from any cause or the date of the last follow-up, whichever came first, assessed up to 12 years
Secondary Outcomes
- Disease-specific survival(From date of diagnosis until death due to PanNETs, up to 12 years)
- Progression-free survival(From date of diagnosis until the date of disease recurrence or death from any cause, whichever came first, assessed up to 12 years.)
- Disease-free survival(From date of surgery until first documented recurrence, metastasis, or death from any cause, assessed up to 12 years.)
Investigators
Hanxiang Zhan
Chief Physician, Department of Pancreatic Surgery
Qilu Hospital of Shandong University